Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

This study has been completed.
Information provided by (Responsible Party):
Merrimack Pharmaceuticals Identifier:
First received: January 10, 2013
Last updated: December 15, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)